-- Company Delivers Fourth Consecutive Quarter of U.S. Revenue Stabilization, Positive Fourth Quarter Cash Flow and Continued Progress on European Reimbursements -- -- Amarin to Present at 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023 -- DUBLIN, Ireland and BRIDGEWATER, N.J.,

-- Company Delivers Fourth Consecutive Quarter of U.S. Revenue Stabilization, Positive Fourth Quarter Cash Flow and Continued Progress on European Reimbursements -- -- Amarin to Present at 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023 -- DUBLIN, Ireland and BRIDGEWATER, N.J.,

-- Dr. Stewart Brings More Than 30 Years of Cardiometabolic Academic and Industry Experience to Amarin’s Board –- - - Ongoing Board Refreshment Program Has Led to Approximately 70% New Independent Directors Named to the Board Over the Last 12 Months -- DUBLIN, Ireland and BRIDGEWATER, N.J., Jan.

-- Dr. Stewart Brings More Than 30 Years of Cardiometabolic Academic and Industry Experience to Amarin’s Board –- - - Ongoing Board Refreshment Program Has Led to Approximately 70% New Independent Directors Named to the Board Over the Last 12 Months -- DUBLIN, Ireland and BRIDGEWATER, N.J., Jan.

DUBLIN, Ireland and BRIDGEWATER, N.J., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, is scheduled to participate at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023.

DUBLIN, Ireland and BRIDGEWATER, N.J., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, is scheduled to participate at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023.

-- Amarin Continuing Process for Obtaining National Pricing and Reimbursement in Switzerland in the Course of 2023 -- -- Swissmedic Approval Underpins Company’s Presence and Expansion in Switzerland as its Regional Commercial Hub for Europe -- DUBLIN, Ireland and BRIDGEWATER, N.J., Dec.

-- Amarin Continuing Process for Obtaining National Pricing and Reimbursement in Switzerland in the Course of 2023 -- -- Swissmedic Approval Underpins Company’s Presence and Expansion in Switzerland as its Regional Commercial Hub for Europe -- DUBLIN, Ireland and BRIDGEWATER, N.J., Dec.

-- VAZKEPA® Approved in Australia to Reduce the Risk of CV Events in Adult Statin-Treated Patients with High CV Risk with Elevated Triglycerides -- -- Marks Fifth Regulatory Approval for VASCEPA®/VAZKEPA® Franchise in Key International Markets in 2022 -- DUBLIN, Ireland and BRIDGEWATER, N.J., Nov.

DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, is scheduled to participate at the Jefferies London Healthcare Conference.